In this study, a new transdermal vehicle was evaluated using progesterone, estradiol, estradiol + estriol (Biest) and ketoprofen administered as model drugs. For all drugs, sufficient amounts were delivered to achieve a systemic effect, and it was also possible to decrease the amount of emulsion applied.

This study aimed to investigate the potential of Trichosol™, associated with Minoxidil (3%), in the promotion of hair growth. The results indicated that after treatment for 90 days with the combination of Minoxidil (3%) and Trichosol™, both sexes presented increase in the percentage of anagen phase.

This study aimed to evaluate the toxicity of progesterone (P4F) and estradiol (E2F) and their effect complexed into cyclodextrins, and evaluate them as endocrine disruptors through biological parameters of Danio rerio. According to these results, there is a higher toxicity effect of hormones in the free form.

This study aimed to evaluate the preliminary feasibility of using Pentravan® to compound dienogest, gestrinone, nimesulide and piroxicam and their vaginal administration to patients with pelvic pain associated with endometriosis (PPRE). Pentravan® seems to be a feasible intravaginal vehicle, particularly for delivery of dienogest and gestrinone for for PPRE treatment.

The study aimed to evaluate the therapeutic effect of two natural extracts, Camellia sinensis (green tea) and resveratrol in the form of oral polymer films, to control halitosis. Results showed a statistically significant reduction in volatile sulfur compound levels in 71.79% of the volunteers.

This study investigated the dermatological effects of oral ingestion of SiliciuMax, either solid or liquid, on the skin, hair and nails of healthy volunteers. Use of SiliciuMax provided significant betterment of wrinkles and UV spots. Changes were also observed in skin texture and eyelash length. Hair aluminium levels decreased.

A reduction in dose-dependent cell viability was observed in treated fibroblasts. When Pinetonin and linole are administered in astrocytic cells, there was a reduction of the intracellular concentration of Ca2+ against a control group treated with DHPG agonist. The evaluation of salivary cortisol demonstrated a reduction in the treated group.

The objective of this study was to evaluate the stability of oral suspensions compounded with SyrSpend SF PH4 and 14 commonly used active pharmaceutical ingredients. The beyond-use date of the final products (API + vehicle) was at least 90 days for all suspensions in the conditions tested.

In this study, the rheological behavior of ready-to-use vehicles for oral pharmaceutical preparations was compared, and the sedimentation of paracetamol dispersed in these vehicles was investigated. With SuspendIt and SyrSpend SF PH4 (Liquid), very stable paracetamol suspensions were obtained. SyrSpend SF PH4 (Liquid) displayed somewhat higher viscosity.

This research evaluated the stability of 12 oral liquid formulations in SyrSpend® SF. A beyond-use date (BUD) of 30 days was assigned to tiagabine HCl 1.0 mg/ml at RT, (90 days refrigerated). 60 days was assigned to chloral hydrate 100.0 mg/ml and 90 days to the rest (RT or refrigerated).